Skip to main content

MS specialist neurology · UK-wide

Multiple sclerosis treatment, by an MS specialist neurology team.

See indicative pricing
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Indicative pricing

What private MS treatment costs in the UK.

Indicative ranges across UK MS centres.

In short

£350–£550, MRI and LP arranged within days.

Service Indicative range
MS neurology consultation (initial) £350–£550
Follow-up MS neurology review £200–£350
MRI brain and cervical cord (with contrast) £800–£1,400
Lumbar puncture with OCB analysis £600–£1,200
First-line oral DMT (monthly, private) £600–£1,100
High-efficacy DMT infusion (per cycle) £3,500–£8,000
IV methylprednisolone relapse course £900–£1,800
AHSCT (NHS-commissioned specialist centre) £75,000–£150,000

Prices vary by centre, by DMT chosen, by monitoring intensity and by whether infusions are given day-case or inpatient. NICE-approved DMTs are commissioned by the NHS at MS specialist centres; private DMT costs are drug plus monitoring plus infusion suite.

The problem

The right neurologist, the right DMT, the right symptom plan.

MS care is one of the most fragmented pathways in UK medicine - long waits, generalist appointments, DMT choices made by what a clinic stocks rather than what your disease is doing. We fix all three before you commit.

  • Diagnosis in the balance?

    McDonald 2017 done properly - MRI, clinical, LP for OCB where needed, NMOSD and MOG-antibody ruled out first.

  • DMT decision looming?

    The full menu weighed against your relapse rate, MRI, EDSS, comorbidity and fertility plans - not just what the clinic infuses.

  • Symptoms left unaddressed?

    Spasticity, fatigue, bladder, pain and mood have specific pathways. We stitch them into one plan alongside the DMT.

When it helps

When specialist MS treatment is the right step.

The scenarios we see most, plus the red flag that means an emergency rather than an appointment.

  • Relapsing-remitting MS (RRMS)

    The commonest onset pattern - around 85% at diagnosis. Discrete relapses with partial or full recovery between; DMTs change the trajectory.

  • Secondary progressive MS (SPMS)

    Accumulating disability after an initial relapsing phase. Fewer DMT options but ocrelizumab and symptom management still matter.

  • Primary progressive MS (PPMS)

    10–15% of people from onset. Progressive from the start; ocrelizumab is the only DMT currently approved.

  • Clinically isolated syndrome (CIS)

    A first neurological episode suggestive of MS. Early MRI and DMT decisions can delay conversion to definite MS.

  • Acute relapse or new MRI activity

    A new attack, or new/enhancing MRI lesions on surveillance - often the trigger to escalate to a higher-efficacy DMT.

  • DMT review or switch

    Breakthrough activity, side effects, JC virus seroconversion on natalizumab, or family planning - reasons to re-open the DMT conversation.

  • Complex symptoms needing MDT

    Spasticity, bladder, pain, fatigue and mood rarely respond to one drug alone - MS nurse, neuro-rehab and specialist input in parallel.

  • Red flag: suspected optic neuritis or myelitis

    Sudden vision loss, severe weakness or bladder retention with sensory level is an emergency - same-day A&E, not a clinic booking.

Treatment options

The full DMT menu, plus relapse and symptom care.

What each option actually involves - and which patients each is best suited to. Shared decision-making, not a menu.

  • First-line / modest-efficacy DMTs

    Interferon-beta (Avonex, Rebif, Plegridy, Betaferon), glatiramer (Copaxone), teriflunomide (Aubagio) and dimethyl fumarate (Tecfidera). Familiar, safer profile, modest relapse reduction.

  • Moderate-efficacy S1P modulators

    Fingolimod (Gilenya), ozanimod (Zeposia) and ponesimod (Ponvory). Oral, once-daily, with cardiac and infection monitoring at initiation.

  • High-efficacy monoclonals

    Natalizumab (Tysabri), ocrelizumab (Ocrevus), ofatumumab (Kesimpta) and off-label rituximab. Strong relapse and MRI-activity control; PML and infection risks to weigh.

  • Induction / immune-reconstitution

    Alemtuzumab (Lemtrada) and cladribine (Mavenclad) - short courses with long tails. Powerful, closely monitored, autoimmunity risk with alemtuzumab.

  • Ocrelizumab for PPMS

    The only DMT approved for primary progressive MS. Six-monthly infusion; the evidence sits mainly with younger patients and active MRI.

  • AHSCT for aggressive RRMS

    Autologous haematopoietic stem cell transplantation at Sheffield, Nottingham, Kings or Manchester. Highly effective in the right patient; real toxicity - a specialist decision.

  • Relapse and symptom management

    IV methylprednisolone for acute relapses; baclofen, gabapentin, fampridine, botox, ITB pumps, antimuscarinics and neuromodulation for symptoms - matched to what is actually limiting you.

  • BTK inhibitors on the horizon

    Tolebrutinib, evobrutinib and others in late-phase trials through 2024–25. Not yet standard, but we flag trials where you might fit.

Safety and monitoring

What to expect from a modern MS pathway - honestly.

MS treatment in 2026 is highly individualised. The things worth planning are diagnosis rigour, DMT choice, screening, relapse care, symptom pathways, pregnancy planning and MRI surveillance.

  • Diagnosis follows McDonald 2017

    Dissemination in space and time on MRI, supported by clinical history and - where needed - lumbar puncture for oligoclonal bands. NMOSD and MOG-antibody disease are ruled out before committing to an MS DMT.

  • DMT choice is a shared decision

    Relapse rate, MRI activity, EDSS, comorbidity, fertility plans, needle tolerance and safety appetite all count. The right drug is the one you will actually take and monitor.

  • High-efficacy DMTs need screening

    JC virus antibody index, hepatitis B and C, HIV, TB and vaccinations before natalizumab, ocrelizumab, ofatumumab, alemtuzumab or cladribine. Missed screening is the commonest avoidable harm.

  • Relapses: steroids, then plasma exchange

    IV methylprednisolone 1g/day for 3–5 days (or oral equivalent) is standard for disabling relapses. Plasma exchange is reserved for severe, steroid-refractory attacks in specialist centres.

  • Symptoms deserve equal airtime

    Spasticity, fatigue, bladder, bowel, pain, mood, cognition, sexual function and mobility all have specific pathways - not just “live with it.” Fampridine, botox, ITB, sacral neuromodulation, CBT and neuro-rehab all in the mix.

  • Pregnancy and DMT planning

    Some DMTs are contraindicated (DMF needs a wash-out; teriflunomide has a long half-life and needs active elimination). Glatiramer, interferon-beta and - in selected high-risk cases - natalizumab may be continued. Breastfeeding compatibility varies.

  • MRI surveillance is not optional

    Annual (or more frequent) brain and cord MRI catches subclinical activity that changes the DMT decision long before the next relapse.

  • AHSCT is powerful and toxic

    For aggressive RRMS failing high-efficacy DMTs, autologous stem cell transplant at a UK specialist centre can be transformative - but neutropenic sepsis, infertility and secondary autoimmunity are real. A joint neurology–haematology decision.

  • Red flags

    Sudden vision loss, severe new weakness, bladder retention with a sensory level, or fever on a high-efficacy DMT are not clinic problems - same-day A&E or the MS nurse hotline.

Reading your MS clinic letter

Your MS letter in four parts. Read the last one first.

Whichever DMT was chosen, the letter your MS neurologist sends you keeps to the same shape.

A UK MS neurologist reviewing a patient’s MRI and clinic letter

A quiet reminder

Neurology letters are precise and can read coldly - ask your care team to explain them if anything is unclear.

  1. 01 Header

    MS type, McDonald criteria and current activity

    Whether the diagnosis is RRMS, SPMS or PPMS; how McDonald 2017 criteria were met; and where you sit on relapse rate and MRI activity today.

  2. 02 Technique

    DMT choice, dose and monitoring plan

    Which DMT was chosen and why, the starting dose, and the monitoring schedule - bloods, MRI intervals, JCV index, vaccination and infection screening.

  3. 03 Findings

    Symptom plan and rehab referrals

    Spasticity, fatigue, bladder, bowel, mood, pain, cognition and mobility - with named treatments and neuro-rehab referrals rather than vague reassurance.

  4. 04 Impression

    What to watch for, and when to call

    Read this first: relapse warning signs, DMT-specific side effects, when to use the MS nurse hotline, and when to go straight to A&E.

Recognised by major UK insurers

BupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealix

Cover for MS consultations, MRI and lumbar puncture is usually funded when medically indicated. DMTs on private cover vary widely - many patients use NHS DMT commissioning alongside private consultations.

Frequently asked

Everything we get asked about MS treatment.

Quick answers on diagnosis, DMT choice, relapse care, symptoms, pregnancy and AHSCT.

  • How is MS diagnosed in the UK?

    Diagnosis follows the McDonald 2017 criteria - dissemination in space and time on MRI, supported by the clinical story and, where helpful, a lumbar puncture showing oligoclonal bands unique to CSF. Aquaporin-4 and MOG antibodies are checked to rule out NMOSD and MOG-antibody disease before starting an MS DMT.

  • Which disease-modifying therapy is right for me?

    It depends on your relapse rate, MRI activity, EDSS, safety appetite, fertility plans and comorbidity. NICE-approved options run from modest-efficacy (interferon-beta, glatiramer, teriflunomide, dimethyl fumarate) through S1P modulators (fingolimod, ozanimod, ponesimod) to high-efficacy monoclonals (natalizumab, ocrelizumab, ofatumumab), induction therapies (alemtuzumab, cladribine) and - in aggressive cases - AHSCT. It is a shared decision, not a menu.

  • Is there a DMT for primary progressive MS?

    Yes - ocrelizumab is the only DMT currently approved for PPMS on the NHS, and the evidence sits mainly with younger patients who still show active MRI lesions. Symptom management and neuro-rehab remain the backbone alongside it.

  • How much does private MS treatment cost in the UK?

    A consultation runs £350–£550, MRI brain and cord £800–£1,400, and lumbar puncture with OCB analysis £600–£1,200. Private DMTs range from £600–£1,100 a month for first-line oral drugs to £3,500–£8,000 per cycle for high-efficacy infusions. AHSCT is NHS-commissioned at £75,000–£150,000 through specialist centres.

  • How are MS relapses treated?

    Disabling relapses are treated with IV methylprednisolone 1g/day for 3–5 days (or oral equivalent). Plasma exchange is reserved for severe, steroid-refractory attacks in specialist centres. Steroids shorten the attack - they do not change the long-term disease course, which is why DMTs matter.

  • What about symptoms - spasticity, fatigue, bladder, pain?

    Each has its own pathway. Spasticity: baclofen, gabapentin, tizanidine, botox, intrathecal baclofen for severe. Fatigue: amantadine, modafinil off-label, energy conservation, exercise. Bladder: intermittent catheterisation, antimuscarinics, botox, sacral neuromodulation. Pain: gabapentin, pregabalin, amitriptyline. Mood: CBT, SSRI/SNRI. Mobility: fampridine (Fampyra), gait aids, FES and neuro-rehab.

  • Can I have a baby on a DMT?

    Yes, with planning. DMF needs a wash-out; teriflunomide has a long half-life and needs active elimination. Glatiramer, interferon-beta and - for selected high-relapse-risk women - natalizumab may be continued. Breastfeeding compatibility varies by drug. Plan it with your MS neurologist and MS nurse, not in the delivery suite.

  • Is AHSCT (stem cell transplant) available in the UK for MS?

    Yes - for aggressive RRMS failing high-efficacy DMTs, autologous haematopoietic stem cell transplantation is NHS-commissioned at Sheffield, Nottingham, Kings and Manchester. It can be highly effective but carries real toxicity (neutropenic sepsis, infertility, secondary autoimmunity) - a joint neurology–haematology decision, not a first line.

  • What is on the horizon for MS treatment?

    BTK inhibitors - tolebrutinib, evobrutinib and others - are in late-phase trials through 2024–25 and may add a new mechanism, particularly for progressive disease. We flag trials where you might fit, without overselling them.

Related treatments

Looking for something else?